Plexiform Neurofibromas Treatment Market, by Drug Class (Selumetinib, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anticonvulsants, Others (Tricyclic Antidepressants, etc.)), by Patient Population (Pediatric, Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Dec 2022

Code : CMI5430

Pages :415

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Plexiform Neurofibromas Treatment Market - Driver

Increasing adoption of inorganic strategies such as product approval by regulatory authorities such as Japanese Ministry of Health, Labour and Welfare (MHLW), is expected to drive the global plexiform neurofibromas treatment market over the forecast period. For instance, in September 2022, AstraZeneca, a biopharmaceutical company, announced that the Japanese Ministry of Health, Labour and Welfare (MHLW), approved Koselugo (selumetinib) in Japan for the treatment of plexiform neurofibromas with clinical symptoms, such as pain and disfigurement in paediatric patients three years of age and older.

Global Plexiform Neurofibromas Treatment Market: Restraint

Lack of approved drugs for the treatment of neurofibromatosis Type 1 is anticipated to hamper the growth of the global plexiform neurofibromas treatment market over the forecast period. For instance, in July 2022, according to the data published by the National Center for the Biotechnology Information, selumetinib developed by the AstraZeneca, a biopharmaceutical company, is the only drug approved by the U.S. Food and Drug Administration and European Commission for the treatment of pediatric patients aged 2 years and older suffering from neurofibromatosis type 1 who have inoperable, symptomatic plexiform neurofibromas (PN). Moreover, other symptomatic treatment are followed for the management of the disease.

Global Plexiform Neurofibromas Treatment Market: Key Developments

Increasing adoption of inorganic strategies such as product approval by regulatory authorities such as European Commission is expected to drive the gloal plexiform neurofibromas treatment over the forecast period. For instance, in June 2021, AstraZeneca Plc., a pharmaceutical company, announced that the Koselugo (selumetinib) had been granted conditional approval in the European Union for the treatment of symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1 aged 3 years and above. The approval by the European Commission was based on positive results from the SPRINT Stratum 1 Phase II trial sponsored by the National Institute of Health's National Cancer Institute Cancer Therapy Evaluation Program. The SPRINT Phase II trial indicated that Koselugo (selumetinib) reduced the tumor volume in children, reducing the pain.